Amani B, Khodavirdilou L, Rajabkhah K, Kardan Moghaddam V, Akbarzadeh A, Amani B. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis. World J Virol 2024; 13(1): 88660 [PMID: 38616851 DOI: 10.5501/wjv.v13.i1.88660]
Corresponding Author of This Article
Bahman Amani, MSc, Researcher, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Qods Street, Keshavarz Blvd, Tehran 1416634793, Iran. b89amani@yahoo.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Behnam Amani, Bahman Amani, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran
Lida Khodavirdilou, Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, United States
Kourosh Rajabkhah, Deputy of Research and Technology, Tehran University of Medical Sciences, Tehran 1416634793, Iran
Vida Kardan Moghaddam, School of Medicine and Dentistry, Griffith University, Queensland, Brisbane 4222, Australia
Arash Akbarzadeh, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran
Author contributions: Amani B designed and administrated the study, and drafted the manuscript; Khodavirdilou L and Kardan Moghaddam V carried out the literature search; Kardan Moghaddam V and Akbarzadeh A performed the data extraction; Rajabkhah K and Kardan Moghaddam V were involved in assessing the quality of studies; Amani B and Akbarzadeh A performed the data analysis; Amani B and Khodavirdilou L performed the writing, review & editing; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bahman Amani, MSc, Researcher, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Qods Street, Keshavarz Blvd, Tehran 1416634793, Iran. b89amani@yahoo.com
Received: October 4, 2023 Peer-review started: October 4, 2023 First decision: October 9, 2023 Revised: November 9, 2023 Accepted: December 29, 2023 Article in press: December 29, 2023 Published online: March 25, 2024 Processing time: 159 Days and 8.1 Hours
ARTICLE HIGHLIGHTS
Research background
Bamlanivimab, a monoclonal antibody (mAb), has been used as a therapeutic agent for patients with coronavirus disease 2019 (COVID-19). Previous studies have shown that bamlanivimab may be effective in treating COVID-19 patients.
Research motivation
Despite several studies evaluating the clinical benefit of bamlanivimab in COVID-19 patients, there is currently no comprehensive systematic review and meta-analysis assessing its efficacy and safety as a treatment.
Research objectives
This study aims to evaluate the use of bamlanivimab in improving efficacy outcomes compared to other treatments in COVID-19 patients. Additionally, the safety profile of bamlanivimab is compared to control groups.
Research methods
A thorough search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar up to January 25, 2023. Cochrane bias tools were utilized to assess the risk of bias in the included studies. Data analysis was performed using Comprehensive Meta-Analysis software (version 3).
Research results
A total of 30 studies were identified and included in the meta-analysis. The meta-analysis revealed a significant difference between the bamlanivimab and standard of care/placebo groups in terms of mortality rate, hospitalization rate, and emergency department (ED) visits. However, there was no significant difference between the two groups regarding intensive care unit (ICU) admission. When compared to other mAbs, bamlanivimab did not demonstrate superior efficacy in terms of hospitalization rate, mortality rate, ICU admission, and ED visits. No significant difference was observed between the treatment groups in terms of adverse events.
Research conclusions
Although the present results demonstrate the efficacy and safety of bamlanivimab in treating COVID-19, further research is necessary to confirm its effectiveness against novel circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.
Research perspectives
In the future, studies should be focused on the efficacy of bamlanivimab against the current SARS-CoV-2 variants, especially in immunocompromised patients who are more susceptible to the new SARS-CoV-2 variants in terms of mutations and resistance to treatment with mAbs. Moreover, the comorbidity percentage and COVID-19 vaccination rate should be considered in evaluating the efficacy of bamlanivimab in COVID-19 patients.
